国产乱色精品成人免费视频,国产婷婷色一区二区三区在线,八戒八戒午夜视频,国内精品视频一区二区三区八戒

國(guó)藥集團(tuán) Sinopharm
中國(guó)醫(yī)藥集團(tuán)是由國(guó)務(wù)院國(guó)資委直接管理的中國(guó)最大的醫(yī)藥健康產(chǎn)業(yè)集團(tuán)，以預(yù)防治療和診斷護(hù)理等健康相關(guān)產(chǎn)品的分銷、零售、研發(fā)及生產(chǎn)為主業(yè)。中國(guó)醫(yī)藥集團(tuán)成立于1998年，由中國(guó)醫(yī)藥（集團(tuán)）公司、中國(guó)醫(yī)藥工業(yè)公司、中國(guó)醫(yī)藥對(duì)外貿(mào)易總公司、中國(guó)醫(yī)療器械工業(yè)公司4家企業(yè)聯(lián)合組建而成。2003年中國(guó)藥材集團(tuán)進(jìn)入集團(tuán)、2009年集團(tuán)與中國(guó)生物技術(shù)集團(tuán)公司聯(lián)合重組、2010年上海醫(yī)藥工業(yè)研究院、中國(guó)出國(guó)人員服務(wù)總公司進(jìn)入集團(tuán)。目前集團(tuán)旗下?lián)碛惺胰Y或控股子公司，國(guó)藥控股一家H股上市公司及國(guó)藥股份、天壇生物、現(xiàn)代制藥、一致藥業(yè)四家A股上市公司。中國(guó)醫(yī)藥集團(tuán)2011年實(shí)現(xiàn)營(yíng)業(yè)收入超過(guò)1200億元。

中國(guó)醫(yī)藥集團(tuán)正在全力推進(jìn)集團(tuán)五大平臺(tái)——現(xiàn)代物流分銷一體化平臺(tái)、產(chǎn)學(xué)研一體化科技創(chuàng)新平臺(tái)、國(guó)際經(jīng)營(yíng)一體化平臺(tái)、醫(yī)療健康產(chǎn)業(yè)平臺(tái)、高效管控與融合協(xié)同一體化平臺(tái)的全面建設(shè)，依托集團(tuán)五大平臺(tái)協(xié)同運(yùn)作，促進(jìn)集團(tuán)十一個(gè)核心業(yè)務(wù)——醫(yī)藥現(xiàn)代物流分銷、醫(yī)藥零售、生物制品、化學(xué)制藥、現(xiàn)代中藥、診斷試劑與化學(xué)試劑、科學(xué)儀器與醫(yī)療器械、醫(yī)藥科研與工程設(shè)計(jì)、醫(yī)藥國(guó)際經(jīng)營(yíng)與海外實(shí)業(yè)、醫(yī)藥會(huì)展與傳媒、醫(yī)療健康產(chǎn)業(yè)的全面發(fā)展，構(gòu)成了一個(gè)完整的中央企業(yè)醫(yī)藥健康產(chǎn)業(yè)平臺(tái)，實(shí)現(xiàn)了規(guī)模效益，推動(dòng)業(yè)績(jī)高速增長(zhǎng)。2003年至2011年中國(guó)醫(yī)藥集團(tuán)營(yíng)業(yè)收入年平均增幅33%，利潤(rùn)總額年平均增幅44%，總資產(chǎn)年平均增幅35%。目前已擁有覆蓋全國(guó)31個(gè)省、自區(qū)、直轄市的醫(yī)藥流通配送網(wǎng)絡(luò)和與國(guó)際水平接軌的30個(gè)配送中心及生產(chǎn)基地。中國(guó)醫(yī)藥集團(tuán)在國(guó)內(nèi)擁有一流的醫(yī)藥及疫苗、血液制品生產(chǎn)企業(yè)、高水平的科研設(shè)計(jì)院所、覆蓋全國(guó)的營(yíng)銷絡(luò)、大規(guī)模的藥材種植基地及全國(guó)第一的醫(yī)藥會(huì)展，產(chǎn)業(yè)鏈完整。從1980年開(kāi)始先后與國(guó)外的著名跨國(guó)醫(yī)藥公司合作，建立了中國(guó)大冢制藥有限公司、無(wú)錫華瑞制藥有限公司等20家中合資醫(yī)藥生產(chǎn)企業(yè)，與美國(guó)、日本、法國(guó)、英國(guó)、德國(guó)、意大利、韓國(guó)等多個(gè)國(guó)家開(kāi)展了國(guó)際技術(shù)合作項(xiàng)目，并與世界上100多個(gè)國(guó)家和地區(qū)建立了貿(mào)易和合作關(guān)系，有力地促進(jìn)了我國(guó)醫(yī)藥生產(chǎn)經(jīng)營(yíng)和醫(yī)藥行業(yè)管理水平的提高。

中國(guó)醫(yī)藥集團(tuán)以“關(guān)愛(ài)生命、呵護(hù)健康”為企業(yè)理念，其所屬企業(yè)承擔(dān)著全國(guó)搶險(xiǎn)救災(zāi)藥品、生物技術(shù)產(chǎn)品、中藥材、醫(yī)療器械的中央儲(chǔ)備、調(diào)撥和供應(yīng)任務(wù)，在1976年唐山大地震、1998年抗洪搶險(xiǎn)、2003年抗擊非典的戰(zhàn)斗中；在2008年汶川抗震救災(zāi)、2009年防控甲型H1N1流感疫情、2010年玉樹(shù)和舟曲抗震救災(zāi)的現(xiàn)場(chǎng)；在2008年奧運(yùn)會(huì)、2009年國(guó)慶閱兵和2010年上海世博會(huì)等重大事件醫(yī)藥物資儲(chǔ)備與應(yīng)急供應(yīng)，以及2010年國(guó)家麻疹疫苗強(qiáng)化免疫活動(dòng)中，都能看到國(guó)藥人緊張工作的身影，為保障人民的生命健康和社會(huì)穩(wěn)定發(fā)揮了重要作用。同時(shí), 集團(tuán)研發(fā)生產(chǎn)的疫苗出口到印度、泰國(guó)、韓國(guó)、尼泊爾、斯里蘭卡等國(guó)，為當(dāng)?shù)孛癖娊】底龀隽朔e極貢獻(xiàn)。

中國(guó)醫(yī)藥集團(tuán)總公司是中國(guó)化學(xué)制藥工業(yè)協(xié)會(huì)、中國(guó)麻醉藥品協(xié)會(huì)、中國(guó)醫(yī)藥商業(yè)協(xié)會(huì)、中國(guó)醫(yī)藥科研開(kāi)發(fā)促進(jìn)會(huì)、中國(guó)醫(yī)療器械行業(yè)協(xié)會(huì)、中國(guó)中藥協(xié)會(huì)、中國(guó)藥文化研究會(huì)等行業(yè)組織的會(huì)長(zhǎng)或理事長(zhǎng)單位，還是全國(guó)藥品交易會(huì)等重要會(huì)展的主辦和支持單位。

中國(guó)醫(yī)藥集團(tuán)的發(fā)展目標(biāo)是，“十二五”期間，建成涵蓋醫(yī)藥行業(yè)全產(chǎn)業(yè)鏈的，具有行業(yè)帶動(dòng)力和國(guó)際競(jìng)爭(zhēng)力的大型醫(yī)藥健康產(chǎn)業(yè)集團(tuán)，成為進(jìn)入世界500強(qiáng)的第一家中國(guó)醫(yī)藥健康企業(yè)。

China National Pharmaceutical Group Corporation, (Sinopharm) is the largest medical and healthcare group in China which is directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC), with the core businesses of distribution, logistics, retail, scientific research and manufacture of healthcare related products. Associated built on the basis of the four state-owned companies: China National Pharmaceutical (Group) Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade Corporation and China National Medical Equipment Industry Corporation, Sinopharm was established in 1998. In 2003, China National Group Corporation of Traditional & Herbal Medicine joined Sinopharm. In 2009, Sinophrm restructured with China National Bio-tech Group (CNBG). As well as in 2010, Shanghai Institute of Pharmaceutical Industry (SIPI) and China National Service Corporation for Chinese Personnel Working Abroad (CNSC) joined Sinopharm. So far, Sinopharm owns 10 wholly owned or holding subsidiaries, and 5 listed companies including Sinopharm Group Co., Ltd. (01099.HK), China National Medicines Co., Ltd. (600511.SH), Beijing Tiantan Biological Products Co., Ltd. (600161.SH), Shyndec Pharmaceutical Co., Ltd. (600420.SH) and Shenzhen Accord Pharmaceutical Co., Ltd. (200028.SZ). The sales revenue of Sinopharm exceeded RMB 160 billion in 2012. It is the only Chinese pharmaceutical company whose sales revenue exceeds RMB 100 billion.
With all-out efforts, Sinopharm is promoting the overall construction of five major platforms – the modern integrated distribution and logistics platform, the integrated manufacturing and R&D platform for scientific and technological innovation, the integrated globally operational platform, the health care industry platform and the highly efficient control and integration services platform, to comprehensively advance the joint development of the eleven core business sectors of modern pharmaceutical logistics and distribution; medicine retail; biological products; chemical pharmaceuticals; modern TCM; diagnosis reagents and chemical reagents; scientific instruments and medical equipments; medical scientific research and engineering design; pharmaceutical international trade and overseas industry, pharmaceutical exhibitions and media; health care industry. So far, Sinopharm has formed an immense and complete pharmaceutical and healthcare industrial platform, realized the scale effect and promote a high-speed growth. Since Year 2003 to Year 2011, the annual average growth rate of revenue was 33%, the annual average growth rate of gross profit was 44% and the annual average growth rate of total assets was 35%. Besides the largest pharmaceutical and medical distribution network covering 31 provinces, autonomous regions and municipalities and 30 international standard distribution centers and production bases, Sinopharm also owns the first-class manufacturers for medicines, vaccines, blood products, high-level scientific and technological institutes, massive planting bases for medicinal herbs and most of domestic medicine and health care related professional exhibition brands in China. Since 1980s, Sinopharm has cooperated with renowned multinationals, established dozens of Sino-foreign pharmaceutical joint ventures, e.g. China Otsuka Pharmaceutical Co., Ltd. (COP) and Sino-Swed Pharmaceutical Co., Ltd. (SSPC), jointly conducted international technologic programs with companies from the U.S.A., Japan, France, UK., Germany, Italy and Korea, built up collaborative relationship with the clients from over 100 countries and regions. The broad international cooperation have energetically promoted the operation and management ability of the industry in China.
Adhering to the corporate conception of 'Caring for life, attending to health', Sinopharm and its subsidiaries have always undertaken the responsibility of central reserve, allocation and supply of medicines and health care related products against emergencies disasters and epidemics. Sinopharm staff could be found at the emergency sites of various catastrophic disasters and significant events, e.g. Tangshan Earthquake in 1976, fighting against floods in 1998, prevention and treatment of SARS in 2003, earthquake relief of Wenchuan Earthquake in 2008, control of influenza A H1N1 in 2009, earthquake relief effort of Yushu Earthquake and Zhouqu Mudslide in 2010, Beijing Olympic Games in 2008, National Day parade in 2009, Shanghai Expo 2010 and national measles supplementary immunization in 2010. Sinopharm has been playing an important role in nationwide preventing and curing diseases, securing public health and promoting the development of the industry. Meanwhile, Sinopharm has exported vaccines to India, Thailand, South Korea, Nepal, Sri Lanka, etc., which made great contribution to local public health.
Sinopharm is taking leading positions of 9 medical industry associations, e.g. China Pharmaceutical Industry Association (CPIA), China National Narcotic Drugs Association (CNNDA), China Association of Pharmaceutical Commerce (CAPC), China Pharmaceutical Industry Research and Development Association (Sino-PhIRDA), China Association For Medical Devices Industry (CAMDI), China Association of Traditional Chinese Medicine (CATCM), and China Pharmaceutical Culture Society, etc. as well as the organizer of many pharmaceutical and healthcare exhibitions and conferences, e.g. Phram China.
Sinopharm is aiming to be an international pharmaceutical and healthcare group which covering the whole industrial chain and can give strong impetus to the industry as well as the first Chinese pharmaceutical company of the Global Top 500 Corporations during the period of "the 12th Five-Year-Plan".